A bond between rheumatic diseases and cancer in the elderly: The interleukin-6 pathway.
Int J Rheum Dis
; 24(10): 1317-1320, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1341230
ABSTRACT
Interleukin (IL)-6 is a soluble factor secreted by T lymphocytes, involved in antibody generation by B lymphocytes. The IL-6 pathway has risen as a pivotal pathway implicated in immune regulation and dysregulation in various rheumatic diseases. Nonetheless, elevated IL-6 levels can also play a role in cancer. Targeting the IL-6 pathway has led to innovative therapeutic approaches for rheumatic diseases and for COVID-19, particularly in the elderly. Indeed, tocilizumab, an agent targeting IL-6, has recently amassed significant attention as a promising univocal agent for different conditions. In this viewpoint, we sought to recall and describe the common pathway among osteoarthritis, rheumatoid arthritis, and cancer, suggesting that anti-IL-6 may be considered a jack-of-all-trades against inflammaging in the elderly.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
B-Lymphocytes
/
Rheumatic Diseases
/
Interleukin-6
/
COVID-19
/
Immunity, Cellular
/
Neoplasms
Limits:
Aged
/
Humans
Language:
English
Journal:
Int J Rheum Dis
Journal subject:
Rheumatology
Year:
2021
Document Type:
Article
Affiliation country:
1756-185X.14194
Similar
MEDLINE
...
LILACS
LIS